Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib with Cisplatin and Docetaxel for Resectable NSCLC
NCT02225405Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2015
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 21 days and Major Pathologic Response Rate up to 5 years. Started Apr 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02225405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225405.